Exelixis FY2026 EPS Forecast Boosted by Zacks Research

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Zacks Research boosted their FY2026 earnings per share estimates for shares of Exelixis in a research note issued to investors on Wednesday, August 26th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of $3.18 for the year, up from their prior forecast of $3.12. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.18 per share. Zacks Research also issued estimates for Exelixis’ Q1 2027 earnings at $0.80 EPS, FY2027 earnings at $3.57 EPS and Q1 2028 earnings at $0.96 EPS.

EXEL has been the subject of several other research reports. Wall Street Zen cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. UBS Group set a $55.00 target price on shares of Exelixis in a report on Monday, August 3rd. Stifel Nicolaus boosted their target price on shares of Exelixis from $47.00 to $51.00 and gave the company a “hold” rating in a research report on Thursday, August 6th. Leerink Partners downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 price target for the company. in a report on Thursday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $56.00 price target on shares of Exelixis in a research report on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $50.07.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $55.26 on Friday. Exelixis has a 52 week low of $33.76 and a 52 week high of $57.57. The stock has a market capitalization of $13.69 billion, a P/E ratio of 17.38, a PEG ratio of 1.67 and a beta of 0.44. The stock’s fifty day moving average is $54.52 and its 200 day moving average is $48.96.

Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The firm had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company’s revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.75 EPS.

Insider Activity at Exelixis

In related news, Director Jack L. Wyszomierski sold 3,925 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $50.55, for a total value of $198,408.75. Following the sale, the director directly owned 284,384 shares of the company’s stock, valued at $14,375,611.20. This trade represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sue Gail Eckhardt sold 9,812 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $50.14, for a total value of $491,973.68. Following the transaction, the director directly owned 16,079 shares of the company’s stock, valued at approximately $806,201.06. The trade was a 37.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 23,549 shares of company stock valued at $1,216,894 over the last ninety days. 2.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Exelixis

Several hedge funds and other institutional investors have recently made changes to their positions in EXEL. BlackRock Inc. acquired a new position in Exelixis during the 2nd quarter worth approximately $1,581,991,000. California State Teachers Retirement System boosted its position in Exelixis by 4,875.6% in the second quarter. California State Teachers Retirement System now owns 14,785,373 shares of the biotechnology company’s stock valued at $804,472,000 after buying an additional 14,488,217 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Exelixis by 48.8% during the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after buying an additional 4,477,029 shares during the last quarter. Invesco Ltd. grew its stake in shares of Exelixis by 1.6% during the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock worth $265,379,000 after buying an additional 94,218 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Exelixis by 0.9% during the first quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock worth $184,391,000 after buying an additional 39,920 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast to $3.18 from $3.12 and increased its Q1 2027 estimate to $0.80 from $0.79. Its Q3 2027 forecast also edged higher to $0.93 from $0.92.
• Neutral Sentiment: The analyst firm maintained estimates of $3.57 EPS for FY2027 and $0.96 EPS for Q1 2028, broadly consistent with the figures cited in its updated forecasts.
• Negative Sentiment: Zacks Research lowered its Q4 2026 EPS estimate to $0.81 from $0.83, reduced its Q2 2027 forecast to $0.84 from $0.89, and trimmed its FY2027 estimate to $3.57 from $3.60. These revisions suggest some concern about near-term earnings momentum.
• Negative Sentiment: Zacks Research continues to assign Exelixis a “Strong Sell” rating, despite the modest increases to several estimates. The firm’s current full-year consensus estimate remains $3.18 per share.
• Negative Sentiment: Options activity was unusually bearish on Thursday, with traders purchasing 10,010 put options—about 826% above the average daily volume of 1,081 contracts. While put buying can represent hedging rather than outright bearish speculation, the surge signals elevated downside protection or concern.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.